Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | IL6 | P05231 | 6/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.34 |
| ▸ | DAO | P14920 | 3/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261534 | 0.85 | SCN10A (0.37) | DAO | |
| SCHEMBL9900951 | 0.80 | PLA2G7 (0.41) | TRPA1P2RX3MAOB | |
| SCHEMBL9905081 | 0.80 | MAOB (0.40) | TRPA1MAOB | |
| SCHEMBL15277244 | 0.78 | MET (0.35) | TRPA1METMAOBHTR2ASLC6A4 | |
| SCHEMBL9901634 | 0.78 | POLB (0.41) | TRPA1METHTR2ASLC6A4 | |
| SCHEMBL9904903 | 0.78 | L3MBTL1 (0.39) | — | |
| SCHEMBL9904884 | 0.78 | HCAR2 (0.39) | DAOMAOB | |
| SCHEMBL15262584 | 0.78 | LTA4H (0.43) | DAOMAOB | |
| SCHEMBL9904803 | 0.77 | MMP13 (0.45) | DAOMAOB | |
| SCHEMBL15263042 | 0.76 | SCN9A (0.39) | TRPA1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | TRPA1 1530/4885IL6 2404/4885TLR7 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.